Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MVD | P53602 | 1/20 | 0.47 |
| ▸ | LPAR3 | Q9UBY5 | 8/20 | 0.47 |
| ▸ | LPAR2 | Q9HBW0 | 6/20 | 0.47 |
| ▸ | LPAR1 | Q92633 | 4/20 | 0.47 |
| ▸ | GGPS1 | O95749 | 2/20 | 0.38 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.33 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.33 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.33 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.33 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.33 |
| ▸ | FDPS | P14324 | 1/20 | 0.32 |
| ▸ | MMP1 | P03956 | 1/20 | 0.32 |
| ▸ | MMP2 | P08253 | 1/20 | 0.32 |
| ▸ | MMP3 | P08254 | 1/20 | 0.32 |
| ▸ | MMP8 | P22894 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15780663 | 0.88 | LPAR3 (0.53) | MVDLPAR3LPAR2LPAR1GGPS1 | |
| SCHEMBL15780662 | 0.85 | LPAR3 (0.50) | MVDLPAR3LPAR2LPAR1GGPS1 | |
| SCHEMBL13531689 | 0.83 | MVD (0.47) | MVDLPAR3LPAR2LPAR1GGPS1 | |
| SCHEMBL14365954 | 0.82 | MVD (0.47) | MVDLPAR3LPAR1GGPS1S1PR2 | |
| SCHEMBL15586931 | 0.82 | MVD (0.47) | MVDLPAR3LPAR2LPAR1GGPS1 | |
| SCHEMBL13521069 | 0.82 | MVD (0.47) | MVDLPAR3LPAR2LPAR1GGPS1 | |
| SCHEMBL15780701 | 0.82 | LPAR3 (0.57) | MVDLPAR3LPAR2LPAR1GGPS1 | |
| SCHEMBL16364649 | 0.81 | MVD (0.46) | MVDLPAR3LPAR2LPAR1GGPS1 | |
| SCHEMBL21409643 | 0.80 | LPAR3 (0.48) | MVDLPAR3LPAR2LPAR1 | |
| SCHEMBL1642999 | 0.79 | LPAR3 (0.46) | MVDLPAR3LPAR2LPAR1GGPS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140162984-A1 | PHOSPHONOXY QUINAZOLINE DERIVATIVES AND THEIR PHARMACEUTICAL USE | ASTRAZENECA AB (SE) | 2014-06-12 | — | — | US | claimed |
| EP-1578755-B1 | PHOSPHONOOXY QUINAZOLINE DERIVATIVES AND THEIR PHARMACEUTICAL USE | ASTRAZENECA AB (SE) | 2007-08-22 | — | — | EP | claimed |
| US-20060116357-A1 | Aurora kinases inhibitors; antiproliferative agents; specially for solid and haematological tumors; 2-[[3-({4-[(5-{2-[(3-fluorophenyl)amino]-2-oxoethyl}-1H-pyrazol-3-yl)amino]-quinazolin-7-yl}oxy)propyl](ethyl)amino]ethyl dihydrogen phosphate | ASTRAZENECA AB (SE) | 2006-06-01 | — | — | US | claimed |
| US-20060058523-A1 | Quinazoline compounds | ASTRAZENECA AB (SE) | 2006-03-16 | — | — | US | claimed |
| EP-1578755-A1 | PHOSPHONOOXY QUINAZOLINE DERIVATIVES AND THEIR PHARMACEUTICAL USE | AstraZeneca AB (SE) | 2005-09-28 | — | — | EP | claimed |
| WO-2004058781-A1 | PHOSPHONOOXY QUINAZOLINE DERIVATIVES AND THEIR PHARMACEUTICAL USE | ASTRAZENECA AB (SE) | 2004-07-15 | — | — | WO | claimed |
| WO-2021260582-A1 | COMBINATION OF ANTIBODY-DRUG CONJUGATE AND AURORA B INHIBITOR | ASTRAZENECA UK LIMITED (GB) | 2021-12-30 | — | — | WO | disclosed |
| US-20170128572-A1 | LONG-LIVED GADOLINIUM BASED TUMOR TARGETED IMAGING AND THERAPY AGENTS | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2017-05-11 | — | — | US | disclosed |
| US-9567358-B2 | Methods of treatment using N-(3-fluorophenyl)-2-{3-[(7-{3-[ethyl(2-hydroxyethyl)amino]propoxy}-quinazolin-4-yl)amino]-1H-pyrazol-5-yl}acetamide | ASTRAZENECA AB (SE) | 2017-02-14 | — | — | US | disclosed |
| US-9567358-B2 | Methods of treatment using N-(3-fluorophenyl)-2-{3-[(7-{3-[ethyl(2-hydroxyethyl)amino]propoxy}-quinazolin-4-yl)amino]-1H-pyrazol-5-yl}acetamide | ASTRAZENECA AB (SE) | 2017-02-14 | — | — | US | disclosed |
| WO-2016068220-A1 | METHOD FOR PRODUCING EUSHEARILIDES | 学校法人東京理科大学 | 2016-05-06 | — | — | WO | disclosed |
| US-20150307534-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2015-10-29 | — | — | US | disclosed |
| US-9018191-B2 | Phosphonoxy quinazoline derivatives and their pharmaceutical use | ASTRAZENECA AB (SE) | 2015-04-28 | — | — | US | disclosed |
| US-20070049555-A1 | Indenoisoquinolinone analogs and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION (US) | 2007-03-01 | — | — | US | disclosed |
| US-20060116357-A1 | Aurora kinases inhibitors; antiproliferative agents; specially for solid and haematological tumors; 2-[[3-({4-[(5-{2-[(3-fluorophenyl)amino]-2-oxoethyl}-1H-pyrazol-3-yl)amino]-quinazolin-7-yl}oxy)propyl](ethyl)amino]ethyl dihydrogen phosphate | ASTRAZENECA AB (SE) | 2006-06-01 | — | — | US | disclosed |
| US-20060058523-A1 | Quinazoline compounds | ASTRAZENECA AB (SE) | 2006-03-16 | — | — | US | disclosed |
| EP-1578755-A1 | PHOSPHONOOXY QUINAZOLINE DERIVATIVES AND THEIR PHARMACEUTICAL USE | AstraZeneca AB (SE) | 2005-09-28 | — | — | EP | disclosed |
| EP-1575946-A1 | QUINAZOLINE COMPOUNDS | AstraZeneca AB (SE) | 2005-09-21 | — | — | EP | disclosed |
| WO-2004058752-A1 | QUINAZOLINE COMPOUNDS | ASTRAZENECA AB (SE) | 2004-07-15 | — | — | WO | disclosed |
| WO-2004058781-A1 | PHOSPHONOOXY QUINAZOLINE DERIVATIVES AND THEIR PHARMACEUTICAL USE | ASTRAZENECA AB (SE) | 2004-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058523-A1 | Quinazoline compounds | NDUFS5, ABL1, NDUFS7 | MVD 4235/4885LPAR3 4630/4885LPAR2 4784/4885 |
| US-20140162984-A1 | PHOSPHONOXY QUINAZOLINE DERIVATIVES AND THEIR PHARMACEUTICAL USE | PLK2, ABL1, CYP3A5 | MVD 1497/4885LPAR3 3136/4885LPAR2 3649/4885 |
| US-20170128572-A1 | LONG-LIVED GADOLINIUM BASED TUMOR TARGETED IMAGING AND THERAPY AGENTS | H1-3, H1-2, H1-4 | MVD 4404/4885LPAR3 184/4885LPAR2 517/4885 |
| US-20150307534-A1 | CHEMICAL COMPOUNDS | ABL1, NQO1, NQO2 | MVD 3344/4885LPAR3 4605/4885LPAR2 4678/4885 |
| US-20070049555-A1 | Indenoisoquinolinone analogs and methods of use thereof | TNNI3, IDH2, GLS | MVD 1396/4885LPAR3 2453/4885LPAR2 2408/4885 |
| US-20060116357-A1 | Aurora kinases inhibitors; antiproliferative agents; specially for solid and haematological tumors; 2-[[3-({4-[(5-{2-[(3-fluorophenyl)amino]-2-oxoethyl}-1H-pyrazol-3-yl)amino]-quinazolin-7-yl}oxy)propyl](ethyl)amino]ethyl dihydrogen phosphate | AURKA, AURKC, AURKB | MVD 1688/4885LPAR3 3349/4885LPAR2 3471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.